- Anal cancer
- Bladder cancer
- Chronic lymphocytic lymphoma
- Chronic myeloid leukemia (CML)
- Colon cancer
- Colorectal cancer
- Diffuse large B-cell lymphoma
- Double hit lymphoma
- Essential thrombocytopenia (ET)
- Follicular lymphoma
- Gastrointestinal stromal tumor
- Hairy cell leukemia
- Head and neck cancer
- Leukemia
- Lung cancer
- Lymphoma
- MALT lymphoma
- Marginal zone lymphoma
- Melanoma
- Melanoma skin cancer
- Merkel cell skin cancer
- Myelodysplastic syndrome (MDS)
- Nodular lymphocyte-predominant Hodgkin's lymphoma
- Polycythemia vera
- Prostate cancer
- Rectal cancer
- Sarcoma
- Skin basal cell carcinoma
- Soft tissue sarcoma
- Squamous cell skin cancer
- Thyroid cancer
- Triple hit lymphoma
- Waldenstrom macroglobulinemia
Lee Hartner, MD
Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Radnor
Penn Medicine Provider
About me
- Director, GI-CREP Program
- Clinical Director, Sarcoma Medical Oncology, Pennsylvania Hospital
- Clinical Professor of Medicine (Hematology-Oncology)
My education and training
- Medical School: Tufts University School of Medicine
- Residency: NewYork-Presbyterian/Weill Cornell Medical Center
- Fellowship: Tufts - New England Medical Center
Spoken languages
English
English
Reviews
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Pennsylvania Hospital: On the medical staff, but does not have privileges to treat patients in the hospital.
Qualifications and experience
- Internal Medicine, Hospice and Palliative Medicine
- Medical Oncology, 2005
- Hematology, 2004
- Internal Medicine, 1997
- American College of Physicians, National
- American Society of Clinical Oncology, National
- American Society of Hematology, National
- Connective Tissue Oncology Society, International
- Abramson Cancer Center
- Penn Breast Cancer Program
- Penn Sarcoma Program
- Recognized annually in Philadelphia Magazine's Top Docs issue from 2018 through 2025
Treatments and conditions
Research
Publications
Elghawy M, Stylli J, Kurian M et al. Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single-Institution Cohort Study , Head and Neck: 2026
Alexio G, Hartner L, Diamond M et al. Liposomal Versus Conventional Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas: Observational Multi-Institutional Cohort of 8.5-Year Experience , JCO Oncology Practice: 2026
Kam AE, Zhao F, Meropol NJ et al. Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201 , Oncologist, 31(1): 2025
Mowery YM, Ballman KV, Hong AM et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial , Lancet, 404(10467): 2024,2053-2064
Loggers ET, Chugh R, Federman N et al. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study , Cancer, 130(16): 2024,2812-2821
Chugh R et al THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY , CTOS Annual Meeting: 2023
Van Tine B et al. RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA. , CTOS Annual Meeting: 2023
Gounder M et al. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. , New England Journal of Medcine, 388(10): 2023,898-921
Gounder MM, Razak AA, Somaiah N, et al. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. , J Clin Oncol., 40(22): 2022,2479-2490
Jia H, Roberson D, Luo X, Kovell RC, Hartner L, Harryhill JF. Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report. , Urol Case Rep.: 2022